A Phase 1, Randomised, Double-Blind, Placebo Controlled, Single and Multiple Ascending Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Inzomelid in Healthy Adult Participants as Well as an Open Label Cohort to Confirm the Safety, Pharmacokinetics, and Pharmacodynamics of Inzomelid in Adult Patients With Cryopyrin-Associated Periodic Syndromes
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Emlenoflast (Primary)
- Indications Cryopyrin-associated periodic syndromes; Inflammation
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Inflazome
Most Recent Events
- 26 Mar 2020 Results from this study in healthy volunteers and preliminary analysis from the CAPS part of this study presented in an Inflazome media release.
- 26 Mar 2020 Status changed from recruiting to completed.
- 10 Feb 2020 Planned End Date changed from 1 Jan 2020 to 1 Mar 2020.